Biotech · Public company · Salt Lake City, UT, US
Recursion Pharmaceuticals, Inc.
Ticker RXRX · SEC CIK 0001601830
Track this companyFree. Adds Recursion Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials73 recruiting or active
Pipeline programs7From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline7
- REC-2282Phase 3 · Neurofibromatosis Type 2ClinicalTrials.gov · fetched Nov 12, 2026
- REC-1245Phase 2 · UnresectableClinicalTrials.gov · fetched Nov 12, 2026
- REC-3964Phase 2 · Recurrent Clostridioides Difficile InfectionClinicalTrials.gov · fetched Nov 12, 2026
- REC-4881Phase 2 · AXIN1 Gene MutationClinicalTrials.gov · fetched Nov 12, 2026
- REC-4881Phase 2 · Familial Adenomatous PolyposisClinicalTrials.gov · fetched Nov 12, 2026
- REC-7735Phase 2 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026
- REC-994Phase 2 · Cerebral Cavernous MalformationClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- REC-7735 in Participants With Solid TumorsPHASE1_PHASE2 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07819136 · fetched Nov 12, 2026
- A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerPHASE1_PHASE2 · RECRUITING · started Nov 21, 2024ClinicalTrials.gov NCT06678659 · fetched Nov 12, 2026
- The Clostridioides Difficile Trial of REC-3964PHASE2 · TERMINATED · started Oct 14, 2024ClinicalTrials.gov NCT06536465 · fetched Nov 12, 2026
- A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC MutationPHASE2 · TERMINATED · started Jan 15, 2024ClinicalTrials.gov NCT06005974 · fetched Nov 12, 2026
- Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)PHASE1_PHASE2 · RECRUITING · started Jul 10, 2023ClinicalTrials.gov NCT05552755 · fetched Nov 12, 2026
- Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasPHASE2_PHASE3 · TERMINATED · started Jun 20, 2022ClinicalTrials.gov NCT05130866 · fetched Nov 12, 2026
- The Symptomatic Cerebral Cavernous Malformation Trial of REC-994PHASE2 · COMPLETED · started Mar 17, 2022ClinicalTrials.gov NCT05085561 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 2, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 15, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 21, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 25, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Feb 25, 2026 · fetched Nov 12, 2026